Technology & Innovation that Drives Retention
Powering an integrated, personalized, and holistic approach to digital connectivity
Validated ROI and Patient Value at Scale
Just-in-Time-Interventions (JITI)™
Precise and personalized advanced technology
Medisafe Maestro
An integrated patient experience, reimagined
Care Integration Engine
Technology that revolutionizes patient support
Real-World Data Insights
Exclusive insights from real patient behaviors
Connected Health Platform
Medication Engagement Technology
Built on a foundation of unmatched usability and commercial adoption at its core, Medisfe’s Enterprise Connected Health Platform is the only completely configurable and rapid-ready platform technology to create, launch and maintain digital health solutions with precision and efficiency.
Digital Drug Companion
Medication Engagement Platform
Patients receive complete treatment management through a combination of advanced technology and expert knowledge. Connect patients with an innovative digital platform that drives medication engagement, integrates human support and delivers a holistic care experience.
Download Medisafe:
Just-in-Time-Interventions (JITI™)
Powering the Medisafe platform with advanced technology that drives personalized interventions
Medisafe Maestro
Digitize patient journeys to optimize patient engagement and brand-specific support
Care Integration Engine
Interoperable technology to integrate care and coordination teams into patient journeys
A comprehensive look at patient segments to inform future treatment journeys
Latest From Medisafe
Transforming Pharma Outcomes: Boosting Adherence & Persistence
Summary This case study examines the unmet needs in treatment adherence and persistence among patients with psoriasis, Crohn’s disease, and ulcerative colitis. Despite advances in biologic therapies, real-world evidence indicates nonadherence rates of up to 50% in psoriasis and 65% in inflammatory bowel disease, driving suboptimal outcomes and increased costs (Smith et al., 2021; Nguyen et al., 2019). Pharmaceutical companies face challenges in maintaining…